5-Amino-1MQ

Mechanism of action

Selectively inhibits nicotinamide-N-methyltransferase (NNMT), an enzyme elevated in adipose tissue of obese individuals that catalyzes the methylation of nicotinamide using S-adenosyl methionine (SAM). NNMT inhibition preserves intracellular NAD+ and SAM pools, suppresses lipogenic transcription factors (PPARγ, C/EBPα, SREBP1), reduces triglyceride accumulation in adipocytes, and may upregulate adiponectin. In rodent studies, it has reduced body weight, adipocyte size, and liver adiposity without affecting food intake.

Primary uses

• Experimental fat loss protocols (preclinical rodent data only)
• Biohacker stacks for metabolic health (off-label, unstudied in humans)
• Research tool for NNMT pathway investigation

Typical dosing

→ Full 5-Amino-1MQ dosage guide — community oral ranges (~50–150 mg/day) set against the key fact that this NNMT-inhibitor small molecule has no published human trials.

Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Regulatory status

Not approved by any regulatory agency for any indication. Sold exclusively as a research chemical. No IND filings or clinical trials registered with ClinicalTrials.gov as of early 2026.

Status as of this entry's last review, October 5, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.

What we checked

5-Amino-1MQ has no paper indexed on PubMed under that short name and no human study; three cell and mouse studies use its full chemical name. This section records what can be checked: what it is, its regulatory status on the date below, the research on it and on the enzyme it targets, and every search we ran.

Identity, computed

It is a methylated quinoline with an amino group, so no amino-acid sequence or peptide calculation applies. It is sold beside peptides, which is why the encyclopedia covers it, and the entry marks it as a small molecule.

Regulatory status, read October 5, 2026

Drugs@FDA: 0 records for “5-amino-1MQ”. EMA medicines list: 0 records for “5-amino-1MQ”. Run for semaglutide, the same queries return 6 and 5 records (and the registry search 86 trials), so a zero here is an absence, not a broken search. Not named on the WADA 2026 and 2027 Prohibited Lists. As a substance with no current approval for human therapeutic use, it falls under section S0 (non-approved substances), which is prohibited at all times; the lists were read on September 27, 2026.

What the maker or sellers claim

Claim, from research-chemical sellers: 5-Amino-1MQ melts fat, raises NAD+ and reverses metabolic ageing in people. No human study of it has been published.

About NNMT inhibitors, not this exact compound

5-Amino-1MQ belongs to a series of nicotinamide N-methyltransferase (NNMT) inhibitors made at the University of Texas Medical Branch. In that group's 2018 paper, a potent member of the series reduced weight and fat in mice made obese on a high-fat diet and improved plasma lipids, with inhibitor selectivity and cell permeability tested first (Neelakantan et al., 2018). A separate company's NNMT inhibitor, JBSNF-000088, lowered body weight and improved insulin sensitivity in obese mice, with no effect in mice lacking the enzyme, which supports NNMT as the target (Kannt et al., 2018). Both are mouse results.

Three later studies name the compound itself, all preclinical. In 2022, obese mice given 5-amino-1-methylquinolinium with a switch to a low-fat diet returned to lean weight and fat faster than with the diet alone. In cancer research it slowed cervical cancer cells in a dish (2021) and, in 2024, reduced bladder tumour growth in mice and strengthened an immunotherapy antibody. None tested it in people.

What we looked for and did not find

No human trial, no registry record, no pharmacokinetic data in people and no dose from a controlled human study.

References

1. [pubmed] Neelakantan H, et al. "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice." Biochem Pharmacol, 2018;147:141-152. PMID: 29155147.
2. [pubmed] Dimet-Wiley A, et al. "Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice." Sci Rep, 2022;12(1):484. PMID: 35013352.
3. [pubmed] Kannt A, et al. "A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders." Sci Rep, 2018;8(1):3660. PMID: 29483571.
4. [pubmed] Akar S, et al. "Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells." J Obstet Gynaecol, 2021;41(8):1240-1245. PMID: 33645410.
5. [pubmed] Yang M, et al. "NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer." J Immunother Cancer, 2024;12(7). PMID: 39067875.
6. [pubmed] Liu JR, et al. "Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes." Biomed Res Int, 2021;2021:9924314. PMID: 34368359.

Related peptides